What’s the Latest on Librela?
Librela is a once-monthly injection to treat pain associated with osteoarthritis in dogs.
Understanding the Concerns, the Science, and Our Approach at Two Rivers Vet Hospital
You may have recently come across headlines or online discussions raising concerns about the use of Librela, the monthly injectable therapy designed to relieve chronic arthritis pain in dogs. A newly circulated study has suggested a potential link between Librela and a rare condition called Rapid Progression of Osteoarthritis (RPOA)—a finding that’s understandably causing some pet parents to pause and reconsider this treatment.
At Two Rivers Veterinary Hospital, we want to address this concern head-on with a clear, science-based perspective. The study in question involved a very small sample of dogs, raising important questions about how generalizable or statistically reliable the findings truly are. While RPOA is indeed listed as a potential side effect of Librela, it’s important to note that multiple independent reviews and clinical trials have shown the risk of this adverse effect to be less than 1 in 1,000 cases. In fact, the majority of dogs treated with Librela experience meaningful relief from joint pain, better mobility, and improved quality of life.
We regularly discuss Librela as an option for dogs who are not responding well to other pain-relieving therapies. When we’ve incorporated it into treatment plans, we’ve often seen excellent results, especially for dogs with advanced osteoarthritis or those who can’t tolerate traditional NSAIDs. Dr. Abby even uses Librela for her own senior dog—a testament to the confidence we place in this medication when used appropriately.
As with any treatment, the decision to use Librela should come from a thoughtful, individualized conversation between you and your veterinarian. Together, we’ll weigh the benefits and risks for your specific pet, considering their medical history, mobility level, and overall response to prior treatments.
We are committed to ongoing education and careful monitoring of every therapy we offer. If new, peer-reviewed research emerges that changes what we know about Librela—or any other medication—we’ll adjust our recommendations accordingly. Your pet’s health and comfort are our top priority, and we remain dedicated to offering only those treatments backed by the best available evidence.
If you have questions about Librela or are wondering whether it’s a good fit for your pet, we’re here to talk. Let’s work together to create a pain management plan that supports your dog’s mobility, happiness, and well-being.
